We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Mar 2022 - 09 Mar 2022
Virtual Venue

Serum MicroRNA Panel Predict P-Tau/Aβ42 in CSF in Alzheimer's Disease

By LabMedica International staff writers
Posted on 29 Nov 2021
Print article
Image: The miRNeasy Serum/Plasma Kit: For purification of cell-free total RNA, including miRNA, from human plasma and serum (Photo courtesy of Qiagen)
Image: The miRNeasy Serum/Plasma Kit: For purification of cell-free total RNA, including miRNA, from human plasma and serum (Photo courtesy of Qiagen)
Amyloid β (Aβ) and tau pathologies are classic characteristic features of Alzheimer’s disease (AD), and they are widely used as diagnostic biomarkers. AD pathology is characterized by the accumulation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the brain.

Aβ and tau in samples of CSF obtained from patients has been shown to diagnose AD with excellent accuracy. Multiple studies have suggested that the combined measurements of phosphorylated-tau (P-tau) and Aβ42 in the CSF can inform a more accurate diagnosis than either test alone.

A team of Neurologists at the Capital Medical University (Beijing, China) extracted RNA samples from the participant's blood. P-tau/Aβ42 of CSF was examined for diagnostic purposes. A pilot study (controls, 21; AD, 23), followed by second (controls, 216; AD, 190) and third groups (controls, 153; AD, 151), was used to establish and verify a predictive model of P-tau/Aβ42 in CSF. The test was then applied to a fourth group of patients with different dementias: AD,155; amnestic mild cognitive impairment (aMCI), 55; vascular dementia (VaD), 51; Parkinson disease dementia (PDD), 53; behavioral variant frontotemporal dementia (bvFTD), 53; dementia with Lewy body (DLB), 52) and 139 controls, to assess its diagnostic capacity

The levels of Aβ42, total-tau (T-tau), and P-tau (tau phosphorylated at Thr 181) in the CSF were then measured using an INNOTEST enzyme-linked immunosorbent assay (ELISA) kits (Fujirebio Diagnostics, Tokyo; Japan). Total RNA was isolated using the miRNeasy Serum Kit (Qiagen, Germantown, MD,USA). For the preparation of the sequencing library, the team used 1 μg of total RNA quantified with Nano Drop 8000 (Thermo Fisher Scientific, Waltham, MA, USA) and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).

The investigators reported that in the pilot study, 29 upregulated and 31 downregulated miRNAs in the AD group were found. In Dataset 2, these miRNAs were then included as independent variables in the linear regression model. A seven-microRNA panel (miR-139-3p, miR-143-3p, miR-146a-5p, miR-485-5p, miR-10a-5P, miR-26b-5p, and miR-451a-5p) accurately predicted values of P-tau/Aβ42 of CSF. In Datasets 3 and 4, by applying the predicted P-tau/Aβ42, the predictive model successfully differentiates AD from controls and VaD, PDD, bvFTD, and DLB.

The authors concluded that the results of their study indicate that a panel of seven miRNAs are potential blood biomarkers for AD. Specifically, the association between the levels of seven miRNAs and the P-tau/Aβ42 ratio in the CSF of AD patients confirms that miRNA biomarkers may reflect pathological changes in the brain and, therefore, can inform the identification of patients with AD. The study was published on November 15, 2021 in the journal BMC Medicine.

Related Links:
Capital Medical University
Fujirebio Diagnostics
Thermo Fisher Scientific
Agilent Technologies

Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT
5-Part Diff Hematology Analyzer
Automatic Urine Sediment Analyzer
3-Part Diff Auto Hematology Analyzer
Cellagon 3

Print article
IIR Middle East



view channel
Image: My Qualiris QC (Photo courtesy of Stago)

Stago Launches New My Qualiris QC Website for Brand-New User Experience

Stago (Paris, France) has launched its new My Qualiris QC website which provides a brand-new user experience with a 24/7 accessible web-application where the results of a user’s network are only a few clicks away.... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.